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The phosphatidylinositol-3 kinase (PI3K)-Akt signaling pathway is known to protect 
a variety of cells from apoptosis.  Phospho-Akt (p-Akt) can facilitate cell survival and 
inactivating pro-apoptotic proteins.  The phosphatase and tensin homologue deleted 
on chromosome ten (PTEN) is a natural biological inhibitor of p-Akt in the PI3K-Akt 
pathway.  The relationship between the expressions of p-Akt and PTEN and pancreatic 
cancer is unknown.  Here, we designed a study to clarify the prognostic signiﬁcance of 
p-Akt and PTEN expression in patients with pancreatic cancer.  Immunohistochemi-
cal analysis of p-Akt and PTEN protein was performed on 51 specimens of pancreatic 
cancer.  The expression of p-Akt was detected in 32 patients (62.7%).  The expression 
of p-Akt was frequently detected in patients with advanced stage pancreatic cancer (P 
= 0.0233).  Patients with p-Akt-positive tumors had signiﬁcantly worse prognoses than 
those with p-Akt-negative tumors (overall survival; 11.3% versus 25.7%).  The expres-
sion of PTEN was detected in 26 patients (51.0%).  Patients with PTEN-positive tumors 
had signiﬁcantly better prognoses than those with PTEN-negative tumors (overall sur-
vival; 29.9% versus 0%).  Patients with p-Akt-positive and PTEN-negative tumors had 
signiﬁcantly worse prognoses than those with p-Akt-negative and PTEN-positive tumors 
(overall survival; 0% versus 39.1%).  Multivariate analysis revealed that expression of 
p-Akt was an independent prognostic factor as well as arterial invasion and lymph node 
metastasis.  The expression of p-Akt and PTEN proteins determined by immunohisto-
chemistry may be a new method for predicting the prognosis of patients with pancreatic 
cancer.
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Patients with pancreatic cancer usually have poor 
prognoses because of high malignancy and resis-
tance to most available chemotherapeutic agents 
due to pancreatic cancer’s resistance to apopto-
tosis (Bardeesy and DePinho, 2002; Heinemann, 
2002; Shi et al., 2002).  In addition, it is difﬁcult 
to cure pancreatic cancer through surgical resec-
tion because it easily invades adjacent tissue. 
Therefore, a new therapeutic modality needs to 
be investigated for treating pancreatic cancer. 
Enhanced understanding of the signaling mecha-
nisms that regulate pancreatic cancer cell growth 
may provide important insights into more effec-
tive therapeutic strategies. 
Abbreviations: p-Akt, phosphorylated-Akt; PI3K, phosphatidylinositol-3 kinase; PTEN, phosphatase and tensin homo-
logue deleted on chromosome ten
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 Akt consists of a family of highly conserved 
serine/threonine kinases.  These kinases are acti-
vated in response to a wide variety of growth fac-
tors through phosphatidylinositol-3 kinase (PI3K). 
Phosphorylation of Akt, which is activated Akt, is 
promoted by phosphatidylinositides converted by 
PI3K products.  Phosphorylated Akt (p-Akt) can 
facilitate cell survival and inactivate pro-apoptotic 
proteins such as Bad and caspase-9 (Datta et al., 
1997; Cardone et al., 1998).  Recently, p-Akt has 
been demonstrated as a major mediator of survival 
signals in a variety of cells including cancer cells 
(Tang et al., 2001).  To date, there have been a few 
studies on the incidence of Akt activation in vari-
ous tumors using archived pathologic specimens. 
In colon cancer, Akt activation was observed in 
patients in advanced clinicopathological stages of 
the disease (Itoh et al., 2002).  In breast cancer, 
Akt activation was frequently observed while 
a worse prognosis was predicted in endocrine-
treated patients (Perez-Tenorio and Stal, 2002). 
Phosphoryklated-Akt by PI3K plays an impor-
tant role in the biological behavior of pancreatic 
cancer and its inhibition may provide a means 
of treatment against pancreatic cancer (Cheng et 
al., 1996; Franke et al., 1995; Hinemann, 2002). 
However, there have been few studies on p-Akt in 
patients with pancreatic cancer.  The phosphatase 
and tensin homologue deleted on chromosome 
ten (PTEN) is a tumor suppressor protein that 
dephosphorylates inositol phospholipid interme-
diates of the PI3K pathway, inhibiting activation 
of downstream targets including Akt (Leslie and 
Downes, 2002).  It has been suggested that the 
loss of PTEN activity causes enhanced cell prolif-
eration, decreased apoptosis and increased tumor 
angiogenesis (Stambolic et al., 1998; Zhong et 
al., 2000).  Several groups have reported loss of 
heterozygosity, mutation or deletion of the gene 
in different cancers, including glioblastoma, pros-
tate, lung and breast carcinomas.  Altered expres-
sion of PTEN has also been detected in various 
precancerous lesions (Li et al., 1997; McMenamin 
et al., 1999; Mutter et al., 2000; Perren et al., 
1999).  However, there have been few studies on 
the role of PTEN as a suppressor of tumor growth 
in patients with pancreatic cancer.
 The relationship between p-Akt and PTEN 
expression in human pancreatic cancer is not yet 
fully understood.  Expression of p-Akt and PTEN 
in pancreatic cancer has not been shown to predict 
tumor malignancy or prognosis.  We hypothesise 
that expression of p-Akt and PTEN may be a nov-
el indicator of advanced stage pancreatic cancer 
or patient prognosis.  In the present study, expres-
sion of p-Akt and PTEN was immunohistochemi-
cally examined in 51 patients with pancreatic 
cancer, and the correlation between expression of 
p-Akt and PTEN and clinicopathological features 




Fifty-one patients who underwent curative resec-
tion of primary pancreatic cancer from October 
1984 to September 2001 were selected for the 
study.  Patient age ranged from 39 to 80 years 
(average 65.2 years); 38 were male and 13 female. 
The clinicopathological ﬁndings were determined 
according to established Tumor-Node-Metastasis 
criteria (Sobin and Wittekind, 2002).  Surgi-
cally resected specimens were macroscopically 
examined to determine tumor location, size and 
invasion of blood vessels.  Tissue samples were 
fixed in 10% formalin and processed by paraf-
fin embedding.  Histological sections were cut, 
stained with hematoxylin and eosin and evaluated 
by pathologists to determine the degree of histo-
logical differentiation, existence of lymph node 
metastasis and invasion of blood vessels.  The 
patients’ progress was followed up until February 
2002.  The follow-up periods for survivors ranged 
from 2 to 127 months (median, 22.8 months) after 
surgery. 
Immunohistochemistry
For immunohistochemical analysis, the strep-
tavidin-biotin method (Histofine SAB-PO kit; 
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Fig. 1. Typical results of p-Akt and PTEN immunohistochemistry.  A: p-Akt-negative cases.  B:  p-Akt-positive cas-
es.  C:  PTEN-negative cases.  D:  PTEN-positive cases (original magniﬁcation, × 100).
Nichirei, Tokyo, Japan) was used for formalin-
ﬁxed and parafﬁn-embedded specimens.  Tissue 
sections were dewaxed in xylene, rehydrated in 
ethanol, and autoclaved at 120°C for 30 min in 
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Table 1. Correlations between p-Akt and PTEN 
expressions
 PTEN  Total
 Negative Positive
p-Akt-negative  6 13 19 (  37.3%)
p-Akt-positive 19 13 32 (  62.7%)
Total 25 (49%) 26 (51%) 51 (100%)
There was a tendency towards a close correlation be-
tween p-Akt and PTEN expression, but the relationship 
between p-Akt and PTEN expression was not signiﬁcant 
(P = 0.0549).  
Target Retrieval Solution (DAKO, Carpentaria, 
CA) for retrieval of antigens.  Endogenous peroxi-
dase was blocked with 0.3% hydrogen peroxide 
in methanol for 20 min.  Tissue sections were 
washed three times with phosphate-buffered sa-
line (PBS) and pre-blocked for 60 min with 10% 
goat serum.  After washing with PBS, the samples 
were incubated at 4°C for 48 h with the follow-
ing primary antibodies: polyclonal antibodies 
rose against p-Akt (Ser 473) (diluted 1:100; Cell 
Signaling Technology, Beverly, MA) and PTEN 
(diluted 1:100; Upstate Cell Signaling Solutions, 
Charlottesville, VA).  Sections were washed three 
times in PBS and incubated with the secondary 
antibody, anti-rabbit immunoglobulin (IgG + IgA 
+ IgM) conjugated with biotin (Nichirei) for 60 
min, followed by incubation with a streptavidin-
peroxidase complex (Nichirei) for 60 min.  After 
three additional washes in PBS, diaminobenzidine 
tetrahydrochloride working solution was applied. 
Finally, the slides were counterstained with hema-
toxylin. 
 All immunostained sections were evaluated 
in a blinded manner with no knowledge of clini-
cal and pathological factors.  p-Akt and PTEN 
expression was not detected in the non-neoplastic 
region of the pancreas.  The intensity of staining 
seen in different areas of the same slide was ana-
lyzed using previously reported criteria (Malik et 
al., 2002).  The intensity is designated as negative 
when no tumor cells are stained, weak when 10–
20% of tumor cells are stained, moderate when 
20–50% of tumor cells are stained, and strong 
when > 50% of tumor cells are stained.  The 
staining pattern was classified as follows: when 
more than ≥ 50% of the tumor cells showed posi-
tive staining, labeling was considered positive, 
and when < 50% of the tumor cells showed posi-
tive staining, labeling was considered negative.
Statistical analysis
Statistical analysis included the standard chi-
square test and Mann-Whitney U test.  The sur-
vival rates were estimated by the Kaplan-Meier 
method, and statistical analysis was carried out 
by the log-rank test for equality of the survival 
curves.  In multivariate analysis, the influ-
ence of each variable on survival was assessed 
by the Cox proportional hazards model and a 
stepwise procedure (StatView 5.0; Abacus Con-
cepts Berkeley, CA).  Statistical significance 
was considered with P < 0.05.
Results
Immunohistochemistry showed that 32 (62.7%) 
of the 51 tumors demonstrated p-Akt-positive 
expression, and 26 (51%) demonstrated PTEN-
positive expression (Table 1).  The typical pattern 
of p-Akt and PTEN staining included both cyto-
plasic and nuclear immunostaining (Fig. 1).
 A tendency towards some close correlation 
between p-Akt and PTEN expression was notice-
able, but there was no signiﬁcant relationship be-
tween p-Akt and PTEN expression (P = 0.0549; 
Table 1).  The correlation between p-Akt or 
PTEN expression and clinicopathological factors 
is shown in Table 2.  p-Akt expression showed no 
correlations with age, gender, histology, venous 
invasion or lymph node metastasis, whereas it was 
signiﬁcantly associated with tumor size, arterial 
invasion and pathological stage.  These data sug-
gest that p-Akt expression was correlated with tu-
mor progression in pancreatic cancer.  On the oth-
er hand, PTEN expression showed no correlation 
with age, tumor size, gender, histology, venous 
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invasion, lymph node metastasis or pathological 
stage, whereas it was signiﬁcantly associated with 
arterial invasion (P = 0.0144).
 Postoperative survival curves for patients 
with pancreatic cancer according to p-Akt and 
PTEN expression are shown in Figs. 2 and 3, re-
spectively.  The estimated 5-year survival rate for 
patients with negative or positive p-Akt expression 
was 25.7 and 11.3%, respectively.  Patients with 
p-Akt-positive tumors had significantly poorer 
prognoses than those with p-Akt-negative tumors 
(P = 0.0132; Fig. 2).  The estimated 5-year sur-
vival rate for patients with negative and positive 
PTEN expression was 0 and 29.9%, respectively. 
Table 2. Correration between expressions of p-Akt or PTEN and clinicopathological factors in 51 
patients with pancreatic cancer
 
     Variable p-Akt PTEN
 Positive (%) Negative (%) P value Positive (%) Negative (%) P value
 
Age† (year)
     < 65      11 (34.4)   9 (47.4)  11 (42.3)    9 (36.0)
     ≥ 65 21 (67.4)   10 (52.6)    NS  15 (57.7) 16 (64.9) NS
Tumor size‡ (cm)  
     < 4.0   13 (44.8)  14 (73.7)  14 (56.0)  13 (56.5) 
     ≥ 4.0   16 (55.2)    5 (26.3) 0.0487 11 (44.0) 10 (43.5) NS
Gender
     Male 25 (78.1)  13 (64.8)  18 (69.2)  20 (80.0)
     Female   7 (21.9)   6 (31.6)    NS   8 (30.8)   5 (20.0) NS
Histology: Invasive ductal carcinoma
     Good 10 (31.3)   7 (36.8)    8 (30.8)   9 (36.0)
     Moderate 20 (62.5)    9 (47.4)  14 (53.8) 15 (60.0)
     Poor   2 (  6.3)   3 (15.8)    NS   4 (15.4)   1 (  4.0) NS
Arterial invasion
     Positive 15 (46.9)    3 (15.8)    5 (19.2) 13 (52.0)
     Negative 17 (53.1)  16 (84.2) 0.0247 21 (80.8) 12 (48.0)        0.0144
Venous invasion
     Positive 14 (43.8)    5 (26.3)    7 (26.9) 12 (48.0)
     Negative 18 (56.3)  14 (73.7)    NS 19 (73.1) 13 (52.0) NS
Lymph node metastasis
     Positive 23 (71.9)  14 (73.7)  16 (61.5) 21 (84.0)
     Negative   9 (28.1)     5 (26.3)    NS 10 (38.5)   4 (16.0) NS
Stage (pTNM)
     I   1 (  3.1)   0 (  0.0)    1 (  3.8)   0 (  0.0)
     II   4 (12.5)   0 (  0.0)    1 (  3.8)   3 (12.0)
     III   5 (15.6) 11 (57.9)  11 (42.3)   5 (20.0)
     IV 22 (68.8)   8 (42.1) 0.0233 13 (50.0) 17 (68.0) NS
† Mean ± SD, 65.2 ± 8.0 years.  
‡ Mean ± SD,   3.9 ± 1.3 cm. 
 NS, not signiﬁcant; pTNM, pathological tumor-node-metastasis. 
 p-Akt-negative expression was more frequently detected in smaller size tumors and in none of the cases with arteri-
al invasion. p-Akt-positive expression was more frequently detected in advanced histological stage tumors. PTEN-
positive expression was detected signiﬁcantly more frequently in patients with no arterial invasion. 
Fig. 2.  Post-operative survival curves of patients with 
pancreatic cancer according to expression of p-Akt.  Pa-
tients with positive p-Akt tumors had signiﬁcantly worse 
prognoses than those with p-Akt-negative tumors (P = 
0.0132).  [  ], number of cases.
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Fig. 5.  Postoperative survival curves of patients with pancreatic cancer in stage IV.  [  ], number of cases.
A: Patients with p-Akt-positive tumors had a signiﬁcantly shorter survival time than those with p-Akt-negative 
tumors (P = 0.02).  
B: Patients with PTEN-positive tumors had a signiﬁcantly longer survival time than those with PTEN-negative 
tumors (P = 0.0386). 
Fig. 3.  Postoperative survival curves of patients with 
pancreatic cancer according to expression of PTEN. 
Patients with PTEN-negative tumors had significantly 
worse prognoses than those with PTEN-positive tumors 
(P = 0.009). [  ], number of cases.
Fig. 4.  Postoperative survival curves of patients with 
pancreatic cancer according to expression of p-Akt and 
PTEN. Patients with p-Akt-positive besides and PTEN-
negative tumors had signiﬁcantly worse prognoses than 
those with p-Akt-negative and PTEN-positive tumors (P 
= 0.0026). [  ], number of cases.
Patients with PTEN-positive tumors had signiﬁ-
cantly better prognoses than those with PTEN-
negative tumors (P = 0.009; Fig. 3).  Patients with 
p-Akt-negative and PTEN-positive tumors had 
signiﬁcantly better prognoses than those with the 
p-Akt-positive and PTEN-negative tumors (39.1% 
versus 0%, respectively; P = 0.0026; Fig. 4).
 In 30 patients with pathological stage IV 
tumors, those with p-Akt-positive tumors had 
a significantly shorter survival time than those 
with p-Akt-negative tumors (P = 0.02; Fig. 5A), 
and patients with PTEN-positive tumors had a 
signiﬁcantly longer survival time than those with 
PTEN-negative tumors (P = 0.0386; Fig. 5B). 
These results suggest that expression of p-Akt and 
PTEN can predict the prognoses of patients with 
pancreatic cancer.
 Multivariate analysis by the Cox propor-
tional hazards model and a stepwise procedure 
was performed to determine the significance of 
the prognoses of patients with pancreatic cancer. 
p-Akt and PTEN expression in pancreatic cancer
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Table 3. Multivariate analysis of prognostic 
factors by the Cox proportion hazard model
 Hazard 95% P
 ratio CI value
p-Akt expression† 2.294 1.078–  4.878  0.0201
Arterial invasion† 6.279 2.902–13.581 < 0.0001
Lymph node metastasis† 4.531 1.962–10.465  0.0005
† Positive or negative. 
 CI, conﬁdence interval.  
 p-Akt Expression, arterial invasion and lymph node 
metastasis are independent prognostic factors in pa-
tients with pancreatic cancer.
Covariates were p-Akt expression, PTEN expres-
sion, histology, venous invasion, arterial invasion, 
lymphatic vessel invasion and pathological stage. 
p-Akt expression, arterial invasion and lymph 
node metastasis were found to be independent 




The PI3K-Akt signaling pathway is known to 
transmit survival signals and to protect a variety 
of cells from apoptosis.  Akt plays a critical role 
in controlling the balance between cell survival 
and apoptosis (Alessi et al., 1997).  It has also 
been reported that Akt plays an important role in 
cell survival when cells are exposed to different 
apoptotic stimuli, such as growth factor with-
drawal, ultraviolet radiation, matrix detachment, 
cell cycle discordance and DNA damage (Burnet 
et al., 1999; Camp et al., 2004).  Phosphoryla-
tion of Akt is promoted by phosphatidylinositides 
converted by PI3K products.  Therefore, when 
phosphorylation of Akt is inhibited, apoptosis 
can be induced (Balendran et al., 1999; Brognard 
et al., 2001).  Inactivation of PI3K using a spe-
ciﬁc inhibitor leads to dephosphorylation of Akt 
at Ser473, consequently causing translocation of 
Akt to the nucleus, where it is believed to regulate 
the transcription of genes mediating cell survival 
or apoptosis (Cardone et al., 1998).  Therefore, 
it is supposed that the PI3K-Akt pathway plays a 
significant role in malignant cells.  There is in-
creasing evidence that Akt is activated in many 
different cancers and that this signaling path-
way confers a potent survival signal (West et al., 
2002).  The tumor suppression gene PTEN is a 
natural biological inhibitor of Akt in cell survival 
signals.  In the present study, we have demon-
strated by immunohistochemistry the frequent 
occurrence of p-AKT and PTEN expression in 
surgically resected pancreatic cancers.  In addi-
tion, our results reveal that p-Akt expression is a 
sign of poor prognosis in patients with pancreatic 
cancer.  Additional investigation is necessary to 
clarify the mechanism that controls p-Akt expres-
sion and activation.  The inhibition of p-Akt may 
be a molecular target for the treatment of pancre-
atic cancer.
  PTEN negatively regulates the PI3-Akt 
pathway and its mutation is associated with an 
aggressive tumor phenotype (Di Cristofano and 
Pandolfi, 2000).  The decreased expression of 
PTEN in pancreatic cancer occurs at the mRNA 
and protein levels, and deletions or mutations are 
not frequently observed (Ebert et al., 2002).  Al-
though it seems clear that the main role of PTEN 
is to regulate the PI3K-Akt pathway, many im-
portant issues remain unresolved in pancreatic 
cancer.  In the present study, we analyzed the 
relationship between p-Akt and PTEN expres-
sion and prognosis of patients with pancreatic 
cancer.  The present immunohistochemical study 
shows a significant association between positive 
PTEN expression and good prognosis.  Our data 
also demonstrate a tendency towards a close cor-
relation between p-Akt and PTEN expression 
(P = 0.00549).  Pancreatic cancer patients with 
p-Akt-negative and PTEN-positive tumors had 
significantly better prognoses than those with 
p-Akt-positive and PTEN-negative tumors.  These 
results suggest that increased expression of PTEN 
inhibits phosphorylation of Akt and subsequently 
the ability of Akt to promote pancreatic cancer 
invasion and resistance to apoptosis.  Although 
additional studies on the mechanism of PTEN are 
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needed, increasing the expression of PTEN pro-
tein may contribute to a new, effective treatment 
for pancreatic cancer.
 In conclusion, we have found that a high ex-
pression level of p-Akt protein is signiﬁcantly cor-
related with poor prognosis, and that high expres-
sion of PTEN protein is significantly correlated 
with good prognoses in patients with pancreatic 
cancer.  Furthermore, it has been suggested that 
patients with negative expression of p-Akt and 
positive expression of PTEN have good prog-
noses.  Therefore, the expression of p-Akt and 
PTEN protein determined by immunohistochem-
istry may be a new method for predicting progno-
ses in patients with pancreatic cancer.  It may be 
that p-Akt and PTEN expression are novel targets 
in the search for effective therapeutic options for 
pancreatic cancer.
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